Icelandic Salmon (ISLAX) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
8 Jul, 2026Executive summary
Q4 2024 saw stabilized biological conditions, higher harvest volumes and weights, effective sea lice control, and strong price performance in North America and Asia.
Full year 2024 harvest was 11,676 tons, down from 17,919 tons in 2023, due to biological challenges in late 2023 and early 2024.
EBIT for Q4 was EUR 1.4 million, impacted by higher costs per kilo and a one-off EUR 600,000 cost from a pox virus outbreak at a smolt facility.
The company secured an additional EUR 65 million in sustainability-linked financing, raising total loan facilities to EUR 160 million.
Financial highlights
Q4 2024 harvest volume was 6,455 tonnes, with a superior share of 94%, and average harvest weight of 5.2 kg, outperforming the Norwegian market average.
Q4 2024 operating income was EUR 49.9 million, down from EUR 51.6 million in Q4 2023.
Operational EBIT for Q4 2024 was EUR 1.4 million; EBIT margin was 3%, and operational EBIT per kg (excluding one-offs) was EUR 0.31.
Net interest-bearing debt including leasing was EUR 86.8 million at year-end, down EUR 2.5 million from the previous period.
Equity ratio improved to 57% at year-end 2024.
Outlook and guidance
2025 volume guidance maintained at 15,000 tonnes, with most harvest expected in H2 2025.
Significant biomass growth and improved MAB utilization anticipated in 2025.
Cost levels expected to be lower in 2025 than 2024, driven by higher volumes and lower feed costs.
Contract share expected at 10% for Q1 and full year 2025.
Long-term growth potential up to 26,000 tonnes on existing licenses.
Latest events from Icelandic Salmon
- Q1 EBIT neared break-even as volumes rose, with stable 2026 outlook despite lower prices.ISLAX
Q1 2026 - Q4 2025 delivered improved results and a positive outlook, with 2026 volume guidance at 21,300 tonnes.ISLAX
Q4 2025 - Operational loss from high costs, but harvest growth and 2026 recovery expected.ISLAX
Q3 2025 - Operational losses and lower guidance amid biological, regulatory, and market challenges.ISLAX
Q2 2025 - Harvest and EBIT were low in Q3, but strong demand and higher volumes are expected in Q4.ISLAX
Q3 2024 - Biological setbacks drove Q2 and H1 losses, but new licenses and ASC certification support growth.ISLAX
Q2 2024 - Biological setbacks and weak prices drove a Q1 2025 loss, but 2025 guidance is unchanged.ISLAX
Q1 2025